Skip to main content

Table 3 Details of serum glycan biomarkers for breast cancer stages based on ROC analysis.

From: Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women

m/z

Glycan structure

Breast cancer (BC) patients vs healthy controls

Can be Biomarker for

BC-I (n = 19)

BC-II (n = 23)

BC-III (n = 25)

BC-IV (n = 24)

Whole BC (N = 95)

AUC

p

AUC

p

AUC

p

AUC

p

AUC

p

1591

0.833

0.014

0.781

0.027

0.630

0.538

0.744

0.555

0.741

P < 0.0001

I

2118

0.858

0.006

0.814

0.001

0.681

1.00

0.708

1.00

0.761

0.002

I, II

2261

0.958

0.029

0.961

0.005

0.886

0.006

0.970

0.02

0.945

P < 0.0001

I- IV, whole BC

2264

0.846

0.13

0.885

0.023

0.856

0.017

0.843

0.309

0.857

P < 0.0001

II, III, whole BC

2337

0.873

P < 0.0001

0.779

0.007

0.650

1.00

0.768

0.034

0.761

P < 0.0001

I

2379

0.868

P < 0.0001

0.844

P < 0.0001

0.725

0.60

0.772

0.016

0.796

P < 0.0001

I, II

2439

0.771

0.359

0.881

P < 0.0001

0.757

0.114

0.862

P < 0.0001

0.821

p < 0.0001

II, IV, whole BC

2525

0.84

0.001

0.795

P < 0.0001

0.773

0.035

814

0.007

0.806

p < 0.0001

I, whole BC

2744

0.765

0.589

0.82

P < 0.0001

0.643

1.00

0.738

0.136

0.739

P < 0.0001

II

3007

0.875

P < 0.0001

0.883

P < 0.0001

0.692

0.603

0.84

0.004

0.818

P < 0.0001

I, II, IV, whole BC

3049

0.827

0.009

0.815

P < 0.0001

0.587

1.00

0.692

0.286

0.721

P < 0.0001

I, II

3109

0.752

0.285

0.839

0.001

0.618

0.954

0.796

0.033

0.751

P < 0.0001

II

3195

0.80

0.003

0.723

0.05

0.755

0.347

0.778

0.102

0.763

P < 0.0001

I

3414

0.816

0.016

0.837

P < 0.0001

0.576

1.00

0.778

0.043

0.747

P < 0.0001

I, II

3560

1

0.003

1

0.018

0.882

0.752

0.935

0.348

0.944

P < 0.0001

whole BC

3719

0.826

0.006

0.871

0.001

0.621

1.00

0.745

0.035

0.762

P < 0.0001

I, II

3865

0.985

0.001

1

0.846

0.963

1.00

0.973

0.927

0.977

P < 0.0001

I, whole BC

  1. AUC value ≥0.8 and level of significant, p ≤ 0.05 at 95% CI were considered as double criteria to evaluate the distinguishing potential of a glycan between patients and normal NC. (AUC value vs diagnostic accuracy: 0.9–1 = “highly accurate”, 0.8–0.9 = “accurate”, 0.7–0.8 = “moderately accurate”, < 0.7 = “uninformative test”). The bold AUC and p-values indicate the glycans at the respective stage could fulfill both the criteria and thus were selected as candidate biomarkers
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us